subject area of
- A new frontier in treatment of advanced melanoma: Redefining clinical management in the era of immune checkpoint inhibitors Journal Articles
- A prime/boost vaccine platform efficiently identifies CD27 agonism and depletion of myeloid-derived suppressor cells as therapies that rationally combine with checkpoint blockade in ovarian cancer Journal Articles
- A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors Journal Articles
- Alterations of immune response of non-small cell lung cancer with Azacytidine Journal Articles
- Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma Journal Articles
- Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events Journal Articles
- Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer Journal Articles
- Immune Checkpoint Inhibitors for Patients With Advanced Non–Small-Cell Lung Cancer: A Systematic Review Journal Articles
- Immune-Checkpoint Induced Skin Toxicity Masked as Squamous Cell Carcinoma: Case Report on Mimickers of Dermatological Toxicity with PD-1 Inhibition Journal Articles
- Impact of Baseline Corticosteroids on Immunotherapy Efficacy in Patients With Advanced Melanoma Journal Articles
- Mechanisms of PD-L1 Regulation in Malignant and Virus-Infected Cells Journal Articles
- Metabolomic adaptations and correlates of survival to immune checkpoint blockade Journal Articles
- Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression Journal Articles
- Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma Journal Articles
-
Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (
PD )‐1 orPD ligand 1 inhibitor therapy Journal Articles - Predictors of Immunotherapy-Induced Immune-Related Adverse Events Journal Articles
- Prognosticating Role of Serum Eosinophils on Immunotherapy Efficacy in Patients with Advanced Melanoma Journal Articles
- Serum Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Prognosticating Immunotherapy Efficacy Journal Articles
- Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma Journal Articles
- The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma Journal Articles
- Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers Journal Articles
- Update on Immunotherapeutics in the Management of Metastatic Melanoma. Journal Articles